Curve Biosciences, Inc.
Have updates for this profile? Please contribute data
= Subscriber Access Only
You are viewing a preview of this profile. Request a Preqin Pro demo for full access to all profiles and underlying data.
With Preqin Pro, you gain an unobstructed view of all alternative asset class activity across institutional investors, fund managers, funds, portfolio companies, deals, exits, and service providers.
Curve Biosciences, Inc. - overview
Established
2021
Location
San Mateo, CA, US
Primary Industry
Software
About
Based in California, US, and founded in 2021, Curve Biosciences, Inc. operates as a biotechnology company that focuses on developing precision medicine that targets the biological changes in tissues that result in the development and progression of chronic diseases. In May 2024, Curve Biosciences, Inc. raised USD 17.
69 million in venture funding. As of May 2024, the company is led by Nathan Hunkapiller (CSO) and Chuba Oyolu (CTO). In October 2025, Curve Biosciences, Inc. raised USD 40 million in venture funding led by new investor Luma Group, with participation from other new investors Civilization Ventures, First Spark Ventures, Incite Ventures, LifeX Ventures, Mintaka, and NZVC.
Individual and other unspecified investors also participated in the round. The company will use the funding to develop its health platform, prepare it for clinical use, and begin offering blood tests. The company leverages a chronic disease tissue atlas and a data-driven approach to discover and develop precision medicine solutions that target chronic illnesses such as liver disease, endometriosis, and inflammatory bowel disease.
Current Investors
Incite Ventures, Civilization Ventures, LifeX Ventures
Primary Industry
Software
Sub Industries
Biotechnology, Medical Software
Website
www.curvebio.com
Verticals
Artificial Intelligence
Company Stage
Series A
Total Amount Raised
Subscriber access only
Time to go Pro
Get Preqin Pro for unrestricted access to 600,000+ detailed profiles on fund managers, investors, funds, companies, and other alternative asset players. Unlock exclusive data on future plans, company financials, fundraising history, track records, and more.